Bevacizumab in Recurrent Grade II and III Glioma

NCT01164189 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

NETWORK

Sponsor class

Conditions

Central Nervous System Tumors

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Temozolomide

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]